Target intelligence / Profile preview

Ubiquitin-conjugating enzyme E2 variant 1 pseudogene

Molecular classification: Pseudogene

Overview

Ubiquitin-conjugating enzyme E2 variant 1 pseudogene (ENSG00000253180) is a pseudogene, meaning it is a DNA segment similar to a known gene (UBE2V1) but lacks the ability to produce a functional protein product. Pseudogenes like this typically arise due to gene duplication or retrotransposition followed by accumulation of disabling mutations. They are considered nonfunctional for encoding proteins, although some pseudogenes in general can have regulatory RNA roles; however, there is no evidence for a known biological or clinical role for ENSG00000253180. This sequence is not a therapeutic target, is not associated with drugs, disease, or biomarker status, and does not pose unique safety or therapeutic challenges.

Other names: UBE2V1 pseudogene

Beyond the preview

Go deeper on Ubiquitin-conjugating enzyme E2 variant 1 pseudogene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 variant 1 pseudogene.

Explore the full profile